SEOM Clinical guidelines for the treatment of metastatic prostate cancer
Clin. transl. oncol. (Print)
; 16(12): 1060-1066, dic. 2014.
Article
en En
| IBECS
| ID: ibc-129876
Biblioteca responsable:
ES1.1
Ubicación: BNCS
ABSTRACT
Androgen deprivation treatment is the current standard first-line treatment for metastatic prostate cancer. For several years, docetaxel was the only treatment with a proven survival benefit for castration-resistant prostate cancer (CRPC). Since docetaxel became standard of care for men with symptomatic metastatic castration-resistant prostate cancer (CRPC), three treatment virtual spaces, for treatment and drug development in CPRC, have emerged pre-docetaxel, docetaxel combinations and post-docetaxel. Sipuleucel-T, cabazitaxel, abiraterone, enzalutamide and radium-223 have been approved in the pre- or post-docetaxel setting in metastatic CRPC during the last few years. Patients are now living longer and experiencing better quality of life. Strategies for patient selection and treatment sequencing are therefore urgently require (AU)
RESUMEN
No disponible
Texto completo:
1
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Neoplasias de la Próstata
/
Andrógenos
/
Antineoplásicos
Tipo de estudio:
Guideline
Aspecto:
Patient_preference
Límite:
Humans
/
Male
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2014
Tipo del documento:
Article